Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595191 | 0.88 | FAAH (0.51) | FAAHTHRBNR1H4LMNARAB9A | |
| SCHEMBL6470532 | 0.88 | HTT (0.58) | FAAHTHRBNR1H4LMNARAB9A | |
| SCHEMBL7861824 | 0.87 | FAAH (0.50) | FAAHTHRBLMNARAB9AMAPT | |
| SCHEMBL21768037 | 0.87 | THRB (0.51) | FAAHTHRBNR1H4LMNARAB9A | |
| SCHEMBL6595861 | 0.86 | FAAH (0.50) | FAAHTHRBLMNAMAPTSMN1; SMN2 | |
| SCHEMBL12519749 | 0.86 | FAAH (0.50) | FAAHTHRBNR1H4RAB9AMAPT | |
| SCHEMBL19363215 | 0.86 | EPHX2 (0.51) | FAAHTHRBLMNAHPGDRAB9A | |
| SCHEMBL7076022 | 0.86 | THRB (0.67) | THRBNR1H4LMNAMAPTSMN1; SMN2 | |
| SCHEMBL12518630 | 0.85 | FAAH (0.49) | FAAHTHRBNR1H4MAPTMEN1 | |
| SCHEMBL31520993 | 0.85 | ITK (0.50) | FAAHTHRBHPGDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005030131-A2 | BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | REPLIDYNE, INC (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | POLI, POLK, POLB | FAAH 2417/4885THRB 3675/4885NR1H4 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.